The 340B Drug Pricing Program is a federal program that requires drug manufacturers to sell outpatient medications at significantly reduced prices to certain hospitals and clinics that serve low-income or underinsured patients. In 2024, participating organizations purchased $81.4 billion worth of drugs through the program, making it one of the largest drug discount programs in the country.
How the Program Works
Created by Congress in 1992, the 340B program is overseen by the Health Resources and Services Administration (HRSA). The core idea is straightforward: drug manufacturers that want their products covered by Medicaid must also agree to sell those same drugs at steep discounts to qualifying healthcare organizations, known as “covered entities.” These organizations can then use the savings to expand services for vulnerable patients.
The discount price, called the “ceiling price,” is calculated using a formula based on a drug’s average manufacturer price minus a mandatory rebate amount. For brand-name drugs, this typically translates to discounts of 25% to 50% off the wholesale price, though some specialty medications see even deeper cuts. HRSA publishes ceiling prices rounded to two decimal places, and manufacturers are prohibited from charging covered entities more than this ceiling.
Who Qualifies as a Covered Entity
Not every hospital or clinic can participate. The program is limited to specific types of organizations that either receive certain federal funding or serve a disproportionate share of low-income patients. Eligible entities fall into four broad categories:
- Federally qualified health centers: community health centers, Native Hawaiian health centers, and tribal and urban Indian health centers
- Ryan White HIV/AIDS Program grantees: clinics funded through the federal program for HIV/AIDS care
- Eligible hospitals: children’s hospitals, critical access hospitals, disproportionate share hospitals, free-standing cancer hospitals, rural referral centers, and sole community hospitals
- Specialized clinics: black lung clinics, hemophilia treatment centers, Title X family planning clinics, sexually transmitted disease clinics, and tuberculosis clinics
These organizations must register with HRSA and meet ongoing eligibility requirements to maintain their 340B status.
Which Patients Are Covered
A common misconception is that any patient walking into a 340B hospital can receive discounted drugs. That’s not the case. HRSA published patient eligibility guidelines more than 25 years ago that still govern how the program operates. Generally, a patient must have an established relationship with the covered entity and receive care from a provider associated with that organization. The covered entity must maintain records of the individual as a patient.
There’s no income test for patients. The eligibility is tied to the healthcare organization, not the patient’s financial situation. If you receive outpatient care at a qualifying hospital or clinic, the drugs prescribed as part of that care can be purchased by the entity at 340B prices, regardless of your insurance status.
How Savings Reach Patients
The program doesn’t require covered entities to pass discounts directly to patients at the pharmacy counter. Instead, organizations use the savings in different ways depending on their patient population’s needs. Ryan White clinics, which provide care for roughly half of all people living with HIV/AIDS in the U.S., report that 340B savings help them offer free or low-cost medications along with support services like housing and food assistance.
Hemophilia treatment centers have used savings to fund care coordination that insurance doesn’t cover, including nurses, social workers, and telemedicine visits. Research comparing 340B hospitals to non-340B hospitals found that 340B participants are more likely to offer medication access services like prior authorization assistance, free or discounted drugs, and outpatient programs for drug treatment or HIV/AIDS care.
The Role of Contract Pharmacies
Many covered entities, especially smaller clinics, don’t operate their own pharmacies. To distribute 340B drugs to their patients, they partner with outside retail pharmacies through what are called contract pharmacy arrangements. A community health center might contract with a nearby chain pharmacy so patients can pick up their 340B-priced prescriptions at a convenient location.
These arrangements have become one of the program’s biggest flashpoints. Starting in late 2020, several drug manufacturers began refusing to honor 340B discounts for medications dispensed through contract pharmacies, arguing the system had grown beyond its original intent and was vulnerable to abuse. The restrictions triggered legal battles and legislative responses. Eight states have passed laws protecting 340B contract pharmacy arrangements, and in Louisiana and Arkansas, those laws prompted more than a dozen manufacturers to lift their restrictions entirely. Advocacy groups have also released model legislation for other states to adopt.
Program Oversight and Compliance
Two major rules govern how covered entities use 340B drugs. First, they cannot “divert” 340B medications to individuals who don’t qualify as patients. Second, they cannot create “duplicate discounts” by billing Medicaid for a drug that was already purchased at the 340B price, since Medicaid already has its own rebate program with manufacturers.
HRSA conducts audits of covered entities and manufacturers to enforce these rules. When violations are found, entities may be required to submit a corrective action plan and issue refunds to drug manufacturers. Failure to submit a corrective action plan can result in removal from the program. Repeated violations of the diversion prohibition across multiple audits can be classified as systematic and intentional, leading to removal from the program and a ban on re-entry for a period of time.
Why the Program Is Controversial
The 340B program has grown substantially since its creation, and that growth has fueled debate. Supporters point to the documented benefits for safety-net providers: more comprehensive services, better medication access, and financial stability for organizations operating on thin margins. Without 340B savings, many of these clinics and hospitals would struggle to keep their doors open or would have to cut programs that uninsured and underinsured patients depend on.
Critics, including some drug manufacturers and policy researchers, argue the program has expanded well beyond its original scope. Large hospital systems with healthy profit margins now participate, and the lack of a federal requirement to pass savings directly to patients raises questions about where the money actually goes. The contract pharmacy model has also drawn scrutiny, with manufacturers contending it creates opportunities for middlemen to profit without clear benefits to patients. There is no federal requirement for covered entities to report how they spend their 340B savings, which makes it difficult to measure the program’s overall impact on patient care.
Both sides agree on one thing: the program has become a major force in the pharmaceutical market, and the policy decisions made around it in the coming years will affect drug pricing, hospital finances, and patient access across the country.